Compound Summary
Compound Information
D-cycloserine
Compound Name: | D-cycloserine |
Compound CID: | 6234 |
Synonyms: | D-cycloserine cycloserine 68-41-7 Seromycin orientomycin More... |
Iupac Name: | (4R)-4-amino-1,2-oxazolidin-3-one |
InChI: | InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1 |
InChIKey: | DYDCUQKUCUHJBH-UWTATZPHSA-N |
Canonical Smiles: | C1C(C(=O)NO1)N |
Isomeric Smiles: | C1[C@H](C(=O)NO1)N |
Molecular Weight: | 102.09 |
Molecular Formula: | C3H6N2O2 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
D-cycloserine
Molecular Weight: | 102.09 |
Molecular Formula: | C3H6N2O2 |
Hydrogen Bond Donor Count: | 2 |
Hydrogen Bond Acceptor Count: | 3 |
Rotatable Bond Count: | 0 |
Heavy Atom Count: | 7 |
Complexity: | 92.9 |
Synonyms
D-cycloserine
| D-cycloserine | D-cycloserine |
|---|---|
D-cycloserine |
cycloserine |
68-41-7 |
Seromycin |
orientomycin |
Oxamycin |
Cyclo-D-serine |
Cyclorin |
D-4-amino-3-isoxazolidinone |
Cicloserina |
Farmiserina |
Miroseryn |
Tisomycin |
Wasserina |
Closina |
D-4-amino-3-isoxazolidone |
alpha-Cycloserine |
(4R)-4-amino-1,2-oxazolidin-3-one |
(+)-4-Amino-3-isoxazolidinone |
Cycloserinum |
Miroserina |
Tebemicina |
Novoserin |
(R)-4-AMINOISOXAZOLIDIN-3-ONE |
(+)-Cycloserine |
Oxamicina |
D-(+)-Cycloserine |
(4R)-4-aminoisoxazolidin-3-one |
PA 94 |
Cycloserin |
Micoserina |
PA-94 |
(R)-4-AMINO-ISOXAZOLIDIN-3-ONE |
D-Oxamycin |
RO-1-9213 |
D-CS |
E-733-A |
3-Isoxazolidinone, 4-amino-, (4R)- |
D-4-Amino-3-isossazolidone |
3-Isoxazolidinone, 4-amino-, (R)- |
HSDB 3218 |
D-Oxamicina |
3-Isoxazolidinone, 4-amino-, d- |
K-300 |
UNII-95IK5KI84Z |
I-1431 |
3-Isoxazolidinone, 4-amino-, (+)- |
NSC 154851 |
CHEBI:40009 |
AI3-50153 |
D-Cycloserine, synthetic |
DCS |
(R)-(+)-4-Amino-3-isoxazolidinone |
CHEMBL771 |
SC-49088 |
95IK5KI84Z |
MFCD00005353 |
CAS-68-41-7 |
NCGC00016306-01 |
Oxamicina Italian |
Cicloserina Italian |
DSSTox_CID_2870 |
3-Isoxazolidinone, 4-amino-, (+)- (8CI) |
DSSTox_RID_76766 |
DSSTox_GSID_22870 |
Cycloserinum INN-Latin |
Cicloserina INN-Spanish |
Cycloserine, D- |
Closerin |
.alpha.-Cycloserine |
(R)-Cycloserine |
Seromycin (TN) |
SMR000058313 |
D-4-Amino-3-isossazolidone Italian |
R-(+)-Cycloserine |
(R)-4-Amino-3-isoxazolidinone |
(4R)-4-Amino-3-isoxazolidinone |
CYCLOSERINE (D) |
SR-01000075432 |
DRG-0195 |
(R)-(+)-Cycloserine |
EINECS 200-688-4 |
D-amino-3-isoxazolidinone |
BRN 0080798 |
(R)-4-Amino-3-isoxazolidone |
NSC-76029 |
cycloserine-(d) |
Serine, cyclo- |
NSC-154851 |
3-Isoxazolidinone, 4-amino-, D |
R(+)-4-Amino-3-isoxazolidinone |
Cycloserine USP:INN:BAN:JAN |
4AX |
3-Isoxazolidinone, 4-amino-, (R) |
Cycloserine, D(+) |
D-Cycloserine, powder |
Spectrum_000860 |
1pb9 |
Prestwick0_001089 |
Prestwick1_001089 |
Prestwick2_001089 |
Prestwick3_001089 |
Spectrum2_000084 |
Spectrum3_000371 |
Spectrum4_000305 |
Spectrum5_000797 |
Lopac-C-1159 |
Lopac-C-3909 |
Lopac-C-7005 |
3-Isoxazolidinone, 4-amino-, (4R)- (9CI) |
C 3909 |
C-9390 |
C-9400 |
Lopac0_000252 |
SCHEMBL34322 |
BSPBio_001138 |
BSPBio_002121 |
KBioGR_000890 |
KBioSS_001340 |
4-27-00-05549 (Beilstein Handbook Reference) |
MLS000758215 |
MLS001423962 |
MLS002548887 |
BIDD:GT0707 |
D-Cycloserine synth. BP 88 |
DivK1c_000098 |
SPECTRUM1500215 |
SPBio_000008 |
SPBio_003029 |
BPBio1_001252 |
FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09 |
GTPL9489 |
Cycloserine (JP17/USP/INN) |
4-Amino-3-isoxazolidinone, D- |
DTXSID8022870 |
HMS500E20 |
KBio1_000098 |
KBio2_001340 |
KBio2_003908 |
KBio2_006476 |
KBio3_001341 |
NINDS_000098 |
HMS1571I20 |
HMS1920C06 |
HMS2051C15 |
HMS2091I14 |
HMS2098I20 |
HMS2232F03 |
HMS3259L19 |
HMS3260D06 |
HMS3715I14 |
NJ-21 |
Pharmakon1600-01500215 |
(R)-3-Isoxazolidinone, 4-amino- |
4-Amino-3-isoxazolidinone, (R)- |
ACT04767 |
HY-B0030 |
Tox21_110361 |
Tox21_500252 |
BDBM50038178 |
BDBM50103516 |
CCG-39705 |
D-Cycloserine, >=96.0% (NT) |
LMPK14000007 |
NSC756712 |
s1998 |
ZINC34676245 |
4-Isoxazolidinamine, 3-oxo-, (D)- |
AKOS015994626 |
Tox21_110361_1 |
AC-4721 |
DB00260 |
HS-0079 |
LP00252 |
MCULE-4212827696 |
NC00050 |
NC00676 |
NSC-756712 |
SDCCGSBI-0050240.P005 |
IDI1_000098 |
SMP1_000167 |
NCGC00015213-01 |
NCGC00015213-02 |
NCGC00015213-03 |
NCGC00016306-02 |
NCGC00016306-03 |
NCGC00016306-04 |
NCGC00016306-05 |
NCGC00016306-07 |
NCGC00016306-08 |
NCGC00016306-17 |
NCGC00093713-01 |
NCGC00093713-02 |
NCGC00260937-01 |
CAS-339-72-0 |
K138 |
ST075697 |
SBI-0050240.P004 |
AB0007232 |
AB00443920 |
EU-0100252 |
(4R)-4-amino-2,4,5-trihydroisoxazol-3-one |
C08057 |
D00877 |
AB00443920_09 |
AB00443920_10 |
005C353 |
101039-EP2295402A2 |
101039-EP2301544A1 |
A836140 |
Q418508 |
SR-01000759389 |
SR-01000075432-1 |
SR-01000075432-2 |
SR-01000075432-5 |
SR-01000075432-9 |
SR-01000759389-4 |
SR-01000075432-10 |
F2173-1228 |
Z1522567171 |
Cycloserine, United States Pharmacopeia (USP) Reference Standard |
Cycloserine, Pharmaceutical Secondary Standard; Certified Reference Material |
(4R)-4-azaniumyl-4,5-dihydroisoxazol-3-olate;(R)-4-AMINOISOXAZOLIDIN-3-ONE |
Experimental Data
D-cycloserine
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33 | umol/L | -4 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
D-cycloserine
Statistics Data
D-cycloserine
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -4 | 1 | 1 |
Statistics Data Visualization
D-cycloserine
